Physician
Oncology
Dr. David M. Friedland, MD
|
|
Give Review
David Friedland works in the field of Oncology. He studied medicine at University of Maryland School of Medicine. University of Maryland School of Medicine has a rank of 37 in research and a 52 in primary care He received 3 awards: "Regional Top Doctor", "CMS Meaningful Use Stage 1 Certification" and "Top MD". Dr. David M. Friedland is also a published doctor. He has 39 paper published. The most recent paper is: Molecular alterations to human chromosome 3p loci in neuroendocrine lung tumors. He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Population Pharmacokinetics of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies.
- Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid Tumors.
- Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies.
- Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases.
- A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.
- Renal Cell carcinoma from a transplanted allograft: two case reports and a review of the literature.
- Radiosurgery for the treatment of spinal Lung metastases.
- Long-term survivors after gamma knife radiosurgery for Brain metastases.
- Stereotactic radiosurgery for spinal metastases from renal Cell carcinoma.
- Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid Tumors.
- A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial Cancer.
- Hypersensitivity reactions from taxol and etoposide.
- Spread of the Spanish multi-resistant serotype 23F clone of Streptococcus pneumoniae to Seoul, Korea.
- First hints in non-small cell lung Cancer (NSCLC).
- CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure inf...
- Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast Cancers.
- Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).
- Endostatin plus interferon-alpha2b therapy for metastatic Melanoma: a novel combination of antiangiogenic and immunomodulatory agents.
- A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate Cancer: correlation of antitumor effect to phosphorylation of Bcl-2.
- Phase II trial of all-trans retinoic acid in metastatic non-small cell lung Cancer.
- A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal Cancer.
- Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced Cancers.
- Phase II study of everolimus (RAD001) in previously treated small cell lung Cancer.
- A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate Cancer.
- A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid Tumors.
- Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
- What should be the routine follow-up after definitive therapy of localized lung Cancer?
- Perioperative therapy of non-small cell lung Cancer: a review of adjuvant and neoadjuvant approaches.
- Recurrent methicillin-resistant Staphylococcus aureus osteomyelitis: combination antibiotic therapy with evaluation by serum bactericidal titers.
- New chemotherapy agents in the treatment of advanced non-small cell lung Cancer: an update including data from the Seventh World Conference on Lung Cancer.
- Properties of chicken erythrocyte delta-aminolevulinate synthase.
- Biogenesis of Liver delta-aminolevulinate synthase. The role of cAMP in the induction.
- The role of oral etoposide in non-small cell lung Cancer.
- Molecular alterations to human chromosome 3p loci in neuroendocrine Lung tumors.
- Small-cell lung Cancer: a perspective on the past and a preview of the future.
- Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.
- Phase II study of carboxyamidotriazole in patients with advanced renal Cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group Study.
- Extraosseous osteoSarcoma of the esophagus: a case report.
Schools
University of Maryland At Baltimore Professional Schools
University Of Pittsburgh
University Of Pennsylvania
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
- Top MD
Education
-
University of Pennsylvania Health System -
University of Maryland School of Medicine
Hospital
-
UPMC Presbyterian Shadyside
Drug Facts
| NPI NUMBER | 1013988021 | |
| NPPES Provider LastName | FRIEDLAND | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 152321301 | |
| NPPES Provider State | PA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 1596.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 181.0 | |
| Percent Opioid Claims | 11.34 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1013988021 |
| Last Name Of The Provider | FRIEDLAND |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. Rafic J. Farah, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donald V. Woytowitz Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Samuel A. Jacobs, MD |
|
|
Dr. Charles H. Srodes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nancy E. Davidson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Enrico M. Novelli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anna M. Johnsen, MD |